DGX QUEST DIAGNOSTICS INC
Services-Medical Laboratories · NYSE · SEC CIK 1022079 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY16.5%
TTM EPS YoY17.8%
Revenue 3-yr CAGR8.4%
Net income 3-yr CAGR14.0%
Margins
Gross margin33.1%
Operating margin14.6%
Net margin9.5%
FCF margin11.6%
EBITDA margin19.5%
Returns
ROE15.2%
ROA6.8%
ROIC (approx.)10.7%
Asset turnover0.71x
Leverage & solvency
Liabilities / assets53.4%
Debt / equity0.73x
Current ratio1.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.73x
Accruals ratio-4.9%
Payout ratio32.7%
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $11.04B | $9.87B |
| Cost of revenue | $7.37B | $6.63B |
| Gross profit | $3.67B | $3.24B |
| SG&A expense | $1.97B | $1.77B |
| Operating income | $1.56B | $1.35B |
| Pretax income | $1.32B | $1.18B |
| Income tax | $314.00M | $273.00M |
| Net income | $992.00M | $871.00M |
| EBITDA | $2.13B | $1.84B |
| EPS (basic) | 8.87 | 7.78 |
| EPS (diluted) | 8.75 | 7.69 |
| Weighted avg. shares (diluted) | 113.00M | 113.00M |
| Banking | ||
| Net interest income | -$264.00M | -$201.00M |
| Balance sheet | ||
| Cash & equivalents | $420.00M | $549.00M |
| Receivables | $1.41B | $1.30B |
| Inventory | $189.00M | $188.00M |
| Current assets | $2.38B | $2.39B |
| PP&E, net | $2.20B | $2.11B |
| Goodwill | $8.95B | $8.86B |
| Intangibles | $1.64B | $1.76B |
| Total assets | $16.23B | $16.15B |
| Current liabilities | $2.28B | $2.17B |
| Short-term debt | $504.00M | $602.00M |
| Long-term debt | $5.17B | $5.62B |
| Total debt | $5.67B | $6.22B |
| Total liabilities | $8.94B | $9.26B |
| Shareholders' equity | $7.17B | $6.78B |
| Net debt | $5.25B | $5.67B |
| Cash flow statement | ||
| Operating cash flow | $1.89B | $1.33B |
| Capital expenditure | $527.00M | $425.00M |
| Free cash flow | $1.36B | $909.00M |
| Investing cash flow | -$631.00M | -$2.55B |
| Financing cash flow | -$1.39B | $1.08B |
| Depreciation & amortization | $570.00M | $493.00M |
| Stock-based compensation | $88.00M | $88.00M |
| Dividends paid | $353.00M | $331.00M |
| Share buybacks | $450.00M | $151.00M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.